

BIOTIME INC  
Form 8-K  
May 13, 2013  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (date of earliest event reported): **May 9, 2013**

**BioTime, Inc.**

(Exact name of registrant as specified in its charter)

<b>California</b>	<b>1-12830</b>	<b>94-3127919</b>
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

**1301 Harbor Bay Parkway**  
**Alameda, California 94502**  
(Address of principal executive offices)

**(510) 521-3390**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

## Forward-Looking Statements

*Any statements that are not historical fact (including, but not limited to statements that contain words such as “may,” “will,” “believes,” “plans,” “intends,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Additional factors that could cause actual results to differ materially from the results anticipated in these forward-looking statements are contained in BioTime’s periodic reports filed with the SEC under the heading “Risk Factors” and other filings that BioTime may make with the Securities and Exchange Commission. Undue reliance should not be placed on these forward-looking statements which speak only as of the date they are made, and the facts and assumptions underlying these statements may change. Except as required by law, BioTime disclaims any intent or obligation to update these forward-looking statements.*

## Section 8 - Other Events

### Item 8.01 - Other Events.

On May 9, 2013, the Office of the Chief Scientist (OCS) of the State of Israel awarded our subsidiary Cell Cure Neurosciences Ltd. a grant of 5.34 million Shekels, approximately \$1.5 million, for 2013 to help finance the development of *OpRegen*<sup>®</sup>, a cell-based therapeutic product in development for the treatment of age-related macular degeneration. Cell Cure Neurosciences’ plans for the development of *OpRegen*<sup>®</sup> include completion of preclinical testing and filing an application to commence human clinical trials in 2014.

The OCS has previously provided grants to Cell Cure Neurosciences. Cell Cure Neurosciences will pay a 3.5% royalty to the OCS on revenues from *OpRegen*<sup>®</sup> until total royalties paid equal 100% of the amount of the grant plus interest at a LIBOR rate.

## Section 9 - Financial Statements and Exhibits

### Item 9.01- Financial Statements and Exhibits.

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release Dated May 13, 2013

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BIOTIME, INC.**

Date: May 13, 2013 By: /s/ Michael D. West  
Chief Executive  
Officer

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release Dated May 13, 2013.